Icon
+91 94997 68112
Login Register

Cabometyx - (20, 40, 60 mg; Tablet, Oral)

Cabozantinib S-Malate Exelixis
20, 40, 60 mg; Tablet, Oral
More Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
None None
Indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy
Yes
*** **** ** ***. ** ****** **** *** *** **** **** ****** ** ***** ****. ** *** **, **** ******* *** **** ** ******* '*** *** '***. ***** ** **** **, **** ******* **** **** ** '***, '*** *** '***. ** *** ****, *** ***** ****** * *********, *********** *** **** ********* *** **** ******* ****** *** ********** ** ****** '*** (**** ** **) ** *** *** ********** ****** ** ************ ** *** ****** *** ***** ** *** ****** ** *****. *** **** *** ** ** **** ****** '*** ** ***** ******* ******* *** ****** ** ** *** ********** ****** '***. ** *** ******** **** ** ****** ***** ** ******* *** **** *** *** **** ****** ** *** ***** ******* **** *** ***** ******. ******** *** **** ******* ********** (*** ******) - *****://**.********.***/******-*****/********-****-****-****-************.
Cabometyx Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12
*** **** **** ** ** ****** **********/ ******** ********* ******* *** ** ** *** ********* *** ********* *** ********* **** ** *** **, **** (***** ******) **** ** *** **, **** (***** ******) **** ** *** **, **** (***** ******) *** ********* (***** ******) **** ** *** **, **** (***** ******) *********
**** *** ********* *** ********* *** ********* ******* ******* ******* *** ********* *** ********* *** ********* *** ********* ******* *** *********
***** *** ********* *** ********* **** ** *** **, **** *** ********* *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, **** *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** **** *** \ ********* ***** **, **** ******* /********* **** ** ** **** ***** *** **, ****
**** **\ ** *** **, **** ******* **** ** *** **, ****
***** ** \ ** *** **, **** ******* **** *** ****** *** **** (******** ******)
  1. *** **, **** : *** **** ******** ******** ***** **'* **** ** ****** ** ****** '***, '***, '***, *** '***.
  2. *** **, **** : ******** ***** * **** ******* *** **** ** ****** ******* (*** *, ****)
  3. *** **, **** : *** **** ****** * *********** ********* **** *** **** **** *** ******** ***-** ****** '***
  4. *** **, **** : ******** ***** * **** ******* *** **** ** ******* '*** *** '***.
  5. *** **, **** : ******** **** **** ** ******* '***, '*** *** '***.
  6. *** *, **** : *** **** ****** ** ************ ** ******* '*** *** '***
  7. *** **, **** : ******** *** *** **** ********* ********** *.*.*. ****** '***
  8. *** **, **** : ******** **** *** **** **** ******* **,***,***, **,***,***, *** **,***,*** *** ******** ** *** **, ****.
  9. *** **, **** : ******** **** *** **** **** ***** ****** ****** '*** (*** **, ****)
  10. *** *, **** : ******** **** **** **** ***** ****** ****** '*** (*** **, ****)
  11. *** **, **** : *** ***** ****** * ********** ** *******, ********* ** ***** *** ****** ** ***** ****** '*** ** ******* *** ******** ****** ** ***** **** *** ********* ****** '***'
  12. *** **, **** : *** **** **** ** ** **** ****** '*** *** *** ** ****** '***
  13. *** *, **** : ***** ******** ******** ** *** ****-** ****** **** ******* '***, '***, '***, '***, *** '***.
  14. *** **, **** : ******** **** ***** **** ************ ** ******* '***, '***, '***, '***, *** '***.
  15. *** **, **** : ******** *** **** ******* ********** *** ********* ** ***** **** *** ****** *** ******* ** *** **, ****.
  16. *** **, **** : ***** ********* ** ******** **** ** ******* ********* ** *** ** ** *********.
  17. *** *, **** : ******** ***** ******* **** ******* ***** **** ************ ** ******* '***, '***, '***, '***, *** '*** ********* ** *** * *********.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.